{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:16:31Z","timestamp":1793132191189,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00277-010-1019-9","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T04:41:44Z","timestamp":1277095304000},"page":"1233-1237","source":"Crossref","is-referenced-by-count":132,"title":["Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients"],"prefix":"10.1007","volume":"89","author":[{"given":"Alejandra","family":"Mart\u00ednez-Trillos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Arellano-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","volume":"51","author":"RJ Jacobson","year":"1978","unstructured":"Jacobson RJ, Salo A, Fialkow PJ (1978) Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189\u2013194","journal-title":"Blood"},{"key":"1019_CR2","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.1999.17.9.2954","volume":"17","author":"G Barosi","year":"1999","unstructured":"Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954\u20132970","journal-title":"J Clin Oncol"},{"key":"1019_CR3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F et al (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 31:737\u201340","journal-title":"Leuk Res"},{"key":"1019_CR4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralowics","year":"2005","unstructured":"Kralowics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u201390","journal-title":"N Engl J Med"},{"key":"1019_CR5","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472\u201376","journal-title":"Blood"},{"key":"1019_CR6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05301.x","volume":"128","author":"F Cervantes","year":"2005","unstructured":"Cervantes F (2005) Modern management of myelofibrosis. Br J Haematol 128:583\u2013592","journal-title":"Br J Haematol"},{"key":"1019_CR7","first-page":"2831","volume":"93","author":"P Guardiola","year":"1999","unstructured":"Guardiola P, Anderson JE, Bandini G et al (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societ\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93:2831\u20132838","journal-title":"Blood"},{"key":"1019_CR8","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Holler E, Kobbe G et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114:5264\u201370","journal-title":"Blood"},{"key":"1019_CR9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E L\u00f6fvenberg","year":"1988","unstructured":"L\u00f6fvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375\u2013381","journal-title":"Eur J Haematol"},{"key":"1019_CR10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.1991.tb07989.x","volume":"77","author":"A Manoharan","year":"1991","unstructured":"Manoharan A (1991) Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 77:252\u2013254","journal-title":"Br J Haematol"},{"key":"1019_CR11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","volume":"115","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian HM, Jain N et al (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood 115:1131\u201336","journal-title":"Blood"},{"key":"1019_CR12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Hood H, Lasho T et al (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2 V617F and MPL W515L\/K mutations. Leukemia 21:1658\u201368","journal-title":"Leukemia"},{"key":"1019_CR13","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood.V112.11.1762.1762","volume":"112","author":"S Verstovsek","year":"2008","unstructured":"Verstovsek S, Kantarjian HM, Pardanani AD et al (2008) The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (post PV\/ET-MF). Blood 112:1762, abstract","journal-title":"Blood"},{"key":"1019_CR14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097","journal-title":"Blood"},{"key":"1019_CR15","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","volume":"106","author":"G Barosi","year":"2005","unstructured":"Barosi G, Bordessoule D, Bri\u00e8re J et al (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 106:2849\u20132853","journal-title":"Blood"},{"key":"1019_CR16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Barosi G, Mesa R et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, from the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497\u2013503","journal-title":"Blood"},{"key":"1019_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","volume":"127","author":"F Cervantes","year":"2004","unstructured":"Cervantes F, Alvarez-Larr\u00e1n A, Hern\u00e1ndez-Boluda JC et al (2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 127:399\u2013403","journal-title":"Br J Haematol"},{"key":"1019_CR18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","volume":"134","author":"Alvarez-Larr\u00e1n A Cervantes","year":"2006","unstructured":"Cervantes Alvarez-Larr\u00e1n A, Hern\u00e1ndez-Boluda JC et al (2006) Efficacy and safety of darbepoetin-alpha in the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 134:184\u2013186","journal-title":"Br J Haematol"},{"key":"1019_CR19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","volume":"129","author":"F Cervantes","year":"2005","unstructured":"Cervantes F (2005) Alvarez Larr\u00e1n A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 129:771\u20135","journal-title":"Br J Haematol"},{"key":"1019_CR20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.1982.00340210131023","volume":"142","author":"LH Brubaker","year":"1982","unstructured":"Brubaker LH, Bri\u00e8re J, Laszlo J et al (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 142:1533\u20131537","journal-title":"Arch Intern Med"},{"key":"1019_CR21","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A et al (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534\u20132541","journal-title":"Blood"},{"key":"1019_CR22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S et al (2006) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108:1158\u201364","journal-title":"Blood"},{"key":"1019_CR23","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","volume":"27","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Verstovsek S, Barosi G et al (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27:4563\u201369","journal-title":"J Clin Oncol"},{"key":"1019_CR24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V15.6.863.863","volume":"15","author":"N Oishi","year":"1960","unstructured":"Oishi N, Swisher SN, Troup SB (1960) Busulfan therapy in myeloid metaplasia. Blood 15:863\u2013872","journal-title":"Blood"},{"key":"1019_CR25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"MC Petti","year":"2002","unstructured":"Petti MC, Latagliata R, Spadea T et al (2002) Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116:576\u2013581","journal-title":"Br J Haematol"},{"key":"1019_CR26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s002770050554","volume":"78","author":"T Bachleitner-Hofmann","year":"1999","unstructured":"Bachleitner-Hofmann T, Gisslinger H (1999) The role of interferon-\u03b1 in the treatment of idiopathic myelofibrosis. Ann Hematol 78:533\u2013538","journal-title":"Ann Hematol"},{"key":"1019_CR27","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagomey DN, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226\u20132233","journal-title":"Blood"},{"key":"1019_CR28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","volume":"103","author":"MA Elliott","year":"1998","unstructured":"Elliott MA, Chen MG, Silverstein MN, Tefferi A (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103:505\u2013511","journal-title":"Br J Haematol"},{"key":"1019_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0609.1990.tb00344.x","volume":"44","author":"E L\u00f6fvenberg","year":"1990","unstructured":"L\u00f6fvenberg E, Wahlin A, Roos G, \u00d6st A (1990) Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 44:33\u201338","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1019-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-1019-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1019-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:49:20Z","timestamp":1591386560000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-1019-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-1019-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}